TLDR
- The FDA approved Lytenava (bevacizumab-vikg) for wet AMD on July 24, two days ahead of the July 29 target date.
- Lytenava is the first and only FDA-approved ophthalmic bevacizumab formulation for wet AMD in the U.S.
- OTLK jumped ~8.9% in pre-market trading Monday, after rising 6% on Friday to $1.41.
- BTIG upgraded OTLK from Neutral to Buy with a $4.00 price target.
- The 12-month average analyst price target is $5.50, implying roughly 290% upside from current levels.
Outlook Therapeutics stock surged in pre-market trading Monday after the FDA approved Lytenava for wet age-related macular degeneration — a milestone the company had been working toward through multiple regulatory cycles.
Outlook Therapeutics, Inc., OTLK
OTLK climbed roughly 8.9% in pre-open trading after gaining 6% on Friday to close at $1.41. The FDA decision arrived on July 24, two business days ahead of the official July 29 PDUFA target date.
Lytenava (bevacizumab-vikg) is now the first and only FDA-approved ophthalmic formulation of bevacizumab developed specifically for wet AMD in the United States.
The road to approval wasn’t smooth. In December 2025, the FDA rejected Outlook’s application and requested more clinical evidence. Outlook appealed the decision, and in May the FDA’s Office of New Drugs ruled that existing data were sufficient — meaning no additional clinical trials were required.
That ruling cleared the way for Outlook to resubmit its application in June, leading directly to Friday’s approval.
The approval was quickly followed by a notable analyst move. BTIG upgraded OTLK from Neutral to Buy and set a $4.00 price target, citing the roughly $8.5 billion U.S. anti-VEGF retina market as the commercial opportunity ahead.
Analyst Targets Range Widely
The broader analyst community is split. Koyfin data shows four covering analysts, with two rating OTLK a Buy and two at Hold. The 12-month average price target sits at $5.50, implying around 290% upside from current levels.
The high target of $10 would represent 609% upside, while the low target of $0.50 would imply a 65% downside.
Bevacizumab has been used in retinal care for over 20 years, but largely on an off-label basis. Outlook estimates millions of eye injections are administered annually in the U.S. alone.
Outlook expects Lytenava to be available to eligible U.S. patients before year-end 2026. The company is building out a specialized retina commercial organization and expanding reimbursement and patient-support access.
European Launch Already Underway
Lytenava is already approved in the European Union and U.K., with commercial launches active in Germany, Austria, and the United Kingdom. Outlook also expects the drug to receive 12 years of U.S. market exclusivity under biologics law.
The company recently regained compliance with Nasdaq’s minimum bid requirement, after holding above $1 for ten consecutive sessions — removing a delisting concern that had hung over the stock for much of the year.
The broader market is also running hot. The S&P 500 gained roughly 1.0%, the Dow rose around 1.0%, and the Nasdaq climbed approximately 1.6% on Monday, providing a tailwind for small-cap biotech names.
BTIG’s $4.00 price target and the BTIG Buy upgrade, issued following the FDA approval, stand as the most recent formal analyst action on the stock.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
